

I have had the chance to attend the ISN World Congress of Nephrology last month in Melbourne. This year, the meeting focussed on glomerulonephritis and integrated end-stage kidney disease. It was the first time I attended this conference, and I must say I particularly enjoyed seeing such a diverse audience. There were presenters and posters from all around the world which was very refreshing. It was heartwarming to see so many people working so hard to improve the life of patients with kidney disease.

I was presenting two posters. The moderated sessions went well, and the attendees asked interesting and relevant questions. I'm sure these discussions will improve my current and future research.

I also attended many talks. My favourite presentation was entitled "Humanizing capitalism to address suffering" which was simply fascinating. I love it when conferences go beyond the expected subjects to bring us exciting topics such as this one. This talk showed us that there is another way for the healthcare industry to make money still while allowing more people to have access to healthcare.

I also like that the conference used other forms of presentation than the traditional lecture. The debate on SGLT2 inhibitors in diabetic kidney disease was both instructive and entertaining. I also enjoyed the interactive quiz on glomerular diseases.

The most memorable highlight of the conference was, of course, the divulgation of the results from the CREDENCE trial. This trial was looking at SGLT2 inhibitors in diabetic nephropathy and was stopped at interim analysis for efficacy. The excitement was palpable in the room. Not only was the quality of the trial remarkable, but the results were also beyond expectations. To finally have something beyond ACE and ARBs in our armamentarium against diabetic nephropathy is truly a relief.

Altogether, I genuinely appreciated the ISN World Congress of Nephrology. I enjoyed the interesting talks, got to present two posters, had many discussions with colleagues, partook in research meetings and workshops and was at the forefront of the latest trials results in nephrology. I sincerely thank the ANZSN for allowing me to attend this remarkable event.